Search

Your search keyword '"Wise, Leanna"' showing total 28 results
Start Over Author "Wise, Leanna" Publication Year Range Last 3 years
28 results on '"Wise, Leanna"'

1. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.

Author

Maguire, Sinead, Al-Emadi, Samar, Alba, Paula, Aguiar, Mathia, Al Lawati, Talal, Alle, Gelsomina, Bermas, Bonnie, Bhana, Suleman, Branimir, Anic, Bulina, Inita, Clowse, Megan, Cogo, Karina, Colunga, Iris, Cook, Claire, Cortez, Karen, Dao, Kathryn, Gianfrancesco, Milena, Gore-Massey, Monique, Gossec, Laure, Grainger, Rebecca, Hausman, Jonathon, Hsu, Tiffany, Hyrich, Kimme, Isnardi, Carolina, Kawano, Yumeko, Kilding, Rachael, Kusevich, Daria, Lawson-Tovey, Saskia, Liew, Jean, McCarthy, Eoghan, Montgumery, Anna, Moyano, Sebastian, Nasir, Noreen, Padjen, Ivan, Papagoras, Charalampos, Patel, Naomi, Pera, Mariana, Pisoni, Cecilia, Pons-Estel, Guillermo, Quiambao, Antonio, Quintana, Rosana, Ruderman, Eric, Sattui, Sebastian, Savio, Veronica, Sciascia, Savino, Sencarova, Marieta, Morales, Rosa, Siddique, Faizah, Sirotich, Emily, Sparks, Jeffrey, Strangfeld, Anja, Sufka, Paul, Tanner, Helen, Tissera, Yohana, Wallace, Zachary, Werner, Marina, Wise, Leanna, Worthing, Angus, Zell, JoAnn, Zepa, Julija, Machado, Pedro, Yazdany, Jinoos, Robinson, Philip, and Conway, Richard

Subjects
COVID-19, patient outcomes, pregnancy, rheumatic disease, vaccination, women’s health, Pregnancy, Infant, Newborn, Female, Humans, COVID-19 Vaccines, COVID-19, COVID-19 Testing, Rheumatic Diseases, Premature Birth, Vaccination
Abstract

OBJECTIVE: To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy. METHODS: Data regarding pregnant women entered into the COVID-19 Global Rheumatology Alliance registry from 24 March 2020-25 February 2022 were analysed. Obstetric outcomes were stratified by number of COVID-19 vaccine doses received prior to COVID-19 infection in pregnancy. Descriptive differences between groups were tested using the chi-squared or Fishers exact test. RESULTS: There were 73 pregnancies in 73 women with RMD and COVID-19. Overall, 24.7% (18) of pregnancies were ongoing, while of the 55 completed pregnancies, 90.9% (50) of pregnancies resulted in livebirths. At the time of COVID-19 diagnosis, 60.3% (n = 44) of women were unvaccinated, 4.1% (n = 3) had received one vaccine dose while 35.6% (n = 26) had two or more doses. Although 83.6% (n = 61) of women required no treatment for COVID-19, 20.5% (n = 15) required hospital admission. COVID-19 resulted in delivery in 6.8% (n = 3) of unvaccinated women and 3.8% (n = 1) of fully vaccinated women. There was a greater number of preterm births (PTB) in unvaccinated women compared with fully vaccinated 29.5% (n = 13) vs 18.2% (n = 2). CONCLUSIONS: In this descriptive study, unvaccinated pregnant women with RMD and COVID-19 had a greater number of PTB compared with those fully vaccinated against COVID-19. Additionally, the need for COVID-19 pharmacological treatment was uncommon in pregnant women with RMD regardless of vaccination status. These results support active promotion of COVID-19 vaccination in women with RMD who are pregnant or planning a pregnancy.

Published
2023

3. Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

Author

Izadi, Zara, Gianfrancesco, Milena A, Aguirre, Alfredo, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Seet, Andrea M, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Al‐Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y‐T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte‐García, Alí, Valenzuela‐Almada, Maria O, Ugarte‐Gil, Manuel F, Ribeiro, Sandra Lúcia Euzébio, de Oliveira Marinho, Adriana, de Azevedo Valadares, Lilian David, Di Giuseppe, Daniela, Hasseli, Rebecca, Richter, Jutta G, Pfeil, Alexander, Schmeiser, Tim, Isnardi, Carolina A, Torres, Alvaro A Reyes, Alle, Gelsomina, Saurit, Verónica, Zanetti, Anna, Carrara, Greta, Labreuche, Julien, Barnetche, Thomas, Herasse, Muriel, Plassart, Samira, Santos, Maria José, Rodrigues, Ana Maria, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Costello, Wendy, Wallace, Zachary S, Yazdany, Jinoos, and Registry, Global Rheumatology Alliance

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Lung, Prevention, Rare Diseases, Arthritis, Autoimmune Disease, Good Health and Well Being, Global Rheumatology Alliance Registry, Clinical sciences
Abstract

ObjectiveSome patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID-19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.MethodsData were derived from the COVID-19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID-19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.ResultsThe study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67-0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%-83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.ConclusionWe were able to predict ARDS with good sensitivity using information readily available at COVID-19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID-19 disease progression.

Published
2022

4. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Author

Izadi, Zara, Gianfrancesco, Milena A, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Ja, Clairissa, Taylor, Tiffany, Shidara, Kie, Danila, Maria I, Wysham, Katherine D, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O, Ugarte-Gil, Manuel F, Ljung, Lotta, Scirè, Carlo A, Carrara, Greta, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Thomas, Thierry, Santos, Maria J, Bernardes, Miguel, Hasseli, Rebecca, Regierer, Anne, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Pons-Estel, Guillermo, Tanten, Romina, Nieto, Romina E, Pisoni, Cecilia N, Tissera, Yohana S, Xavier, Ricardo, Marques, Claudia D Lopes, Pileggi, Gecilmara CS, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Gore-Massy, Monique, Wallace, Zachary S, Yazdany, Jinoos, Registry, COVID-19 Global Rheumatology Alliance, Dahou, Brahim, Gómez, Gimena, Roberts, Karen, Baez, Roberto M, Coello, Vanessa V Castro, Salinas, María J Haye, Maldonado, Federico N, Reyes, Alvaro A, Alle, Gelsomina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan A, Schmid, Maria M, Cosatti, Micaela, Gamba, Maria J, Leandro, Carlevaris, Cusa, María A, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria S Gálvez, Medina, María A, Savio, Veronica, Tessel, Romina Rojas, Alamino, Rodolfo P, Werner, Marina L, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, and Lucero, Luciana Gonzalez

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Women's Health, Social Determinants of Health, Infectious Diseases, Coronaviruses, Emerging Infectious Diseases, Good Health and Well Being, COVID-19 Global Rheumatology Alliance Registry, Clinical sciences
Abstract

BackgroundDifferences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally.MethodsIn this observational study, we derived individual-level data on adults (aged 18-99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death.Findings14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01-1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10-1·30]; p

Published
2022

5. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Author

Ugarte-Gil, Manuel Francisco, Alarcón, Graciela S, Izadi, Zara, Duarte-García, Ali, Reátegui-Sokolova, Cristina, Clarke, Ann Elaine, Wise, Leanna, Pons-Estel, Guillermo J, Santos, Maria Jose, Bernatsky, Sasha, Ribeiro, Sandra Lúcia Euzébio, Al Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Gilbert, Emily L, Valenzuela-Almada, Maria O, Jönsen, Andreas, Landolfi, Gianpiero, Fredi, Micaela, Goulenok, Tiphaine, Devaux, Mathilde, Mariette, Xavier, Queyrel, Viviane, Romão, Vasco C, Sequeira, Graca, Hasseli, Rebecca, Hoyer, Bimba, Voll, Reinhard E, Specker, Christof, Baez, Roberto, Castro-Coello, Vanessa, Ficco, Hernan Maldonado, Neto, Edgard Torres Reis, Ferreira, Gilda Aparecida Aparecida, Monticielo, Odirlei Andre André, Sirotich, Emily, Liew, Jean, Hausmann, Jonathan, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Costello, Wendy, Wallace, Zachary S, Jacobsohn, Lindsay, Taylor, Tiffany, Ja, Clairissa, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schäfer, Martin, Machado, Pedro M, Robinson, Philip C, Gianfrancesco, Milena, and Yazdany, Jinoos

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Infectious Diseases, Lupus, Emerging Infectious Diseases, Minority Health, Coronaviruses, Autoimmune Disease, Women's Health, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Good Health and Well Being, COVID-19, Humans, Lupus Erythematosus, Systemic, Male, Prednisone, Rheumatology, Severity of Illness Index, lupus erythematosus, systemic, epidemiology, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

AimTo determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19.MethodsPeople with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity.ResultsA total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1-5 mg/day 1.86, 1.20 to 2.66, 6-9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab.ConclusionsMore severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes.

Published
2022

7. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Sattui, Sebastian E, Conway, Richard, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Maldonado, Federico Nicolas, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Ugarte-Gil, Manuel, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, Robinson, Philip C, Alliance, Global Rheumatology, Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Ribeiro, Francinne Machado, Ribeiro, Sandra Lucia Euzebio, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Coello, Vanessa Castro, Salinas, María J Haye, Torres, Alvaro Andres Reyes, Alle, Gelsomina, Tanten, Romina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria Soledad Gálvez, Medina, María Alejandra, and Savio, Veronica

Subjects
Aging, Arthritis, Autoimmune Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Global Rheumatology Alliance
Abstract

BackgroundPatients with primary systemic vasculitis or polymyalgia rheumatica might be at a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ damage cause by primary systemic vasculitis, and the demographic factors associated with these conditions. We therefore aimed to investigate factors associated with COVID-19 outcomes in patients with primary systemic vasculitis or polymyalgia rheumatica.MethodsIn this retrospective cohort study, adult patients (aged ≥18 years) diagnosed with COVID-19 between March 12, 2020, and April 12, 2021, who had a history of primary systemic vasculitis (antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, giant cell arteritis, Behçet's syndrome, or other vasculitis) or polymyalgia rheumatica, and were reported to the COVID-19 Global Rheumatology Alliance registry were included. To assess COVID-19 outcomes in patients, we used an ordinal COVID-19 severity scale, defined as: (1) no hospitalisation; (2) hospitalisation without supplemental oxygen; (3) hospitalisation with any supplemental oxygen or ventilation; or (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs), adjusting for age, sex, time period, number of comorbidities, smoking status, obesity, glucocorticoid use, disease activity, region, and medication category. Analyses were also stratified by type of rheumatic disease.FindingsOf 1202 eligible patients identified in the registry, 733 (61·0%) were women and 469 (39·0%) were men, and their mean age was 63·8 years (SD 17·1). A total of 374 (31·1%) patients had polymyalgia rheumatica, 353 (29·4%) had ANCA-associated vasculitis, 183 (15·2%) had giant cell arteritis, 112 (9·3%) had Behçet's syndrome, and 180 (15·0%) had other vasculitis. Of 1020 (84·9%) patients with outcome data, 512 (50·2%) were not hospitalised, 114 (11·2%) were hospitalised and did not receive supplemental oxygen, 239 (23·4%) were hospitalised and received ventilation or supplemental oxygen, and 155 (15·2%) died. A higher odds of poor COVID-19 outcomes were observed in patients who were older (per each additional decade of life OR 1·44 [95% CI 1·31-1·57]), were male compared with female (1·38 [1·05-1·80]), had more comorbidities (per each additional comorbidity 1·39 [1·23-1·58]), were taking 10 mg/day or more of prednisolone compared with none (2·14 [1·50-3·04]), or had moderate, or high or severe disease activity compared with those who had disease remission or low disease activity (2·12 [1·49-3·02]). Risk factors varied among different disease subtypes.InterpretationAmong patients with primary systemic vasculitis and polymyalgia rheumatica, severe COVID-19 outcomes were associated with variable and largely unmodifiable risk factors, such as age, sex, and number of comorbidities, as well as treatments, including high-dose glucocorticoids. Our results could be used to inform mitigation strategies for patients with these diseases.FundingAmerican College of Rheumatology and the European Alliance of Associations for Rheumatology.

Published
2021

8. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry

Author

Yazdany, Jinoos, Ware, Anna, Wallace, Zachary S., Bhana, Suleman, Grainger, Rebecca, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Hausmann, Jonathan S., Liew, Jean W., Sirotich, Emily, Jacobsohn, Lindsay, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Ribeiro, Sandra Lucia Euzebio, Al‐Emadi, Samar, Hasseli, Rebecca, Müller‐Ladner, Ulf, Specker, Christof, Schulze‐Koops, Hendrik, Bernardes, Miguel, Fraga, Vanessa Machado, Rodrigues, Ana Maria, Sparks, Jeffrey A., Ljung, Lotta, Di Giuseppe, Daniela, Tidblad, Liselotte, Wise, Leanna, Duarte‐García, Alí, Ugarte‐Gil, Manuel F., Colunga‐Pedraza, Iris Jazmín, Martínez‐Martínez, Marco Ulises, Alpizar‐Rodriguez, Deshire, Xavier, Ricardo Machado, Isnardi, Carolina A., Pera, Mariana, Pons‐Estel, Guillermo, Izadi, Zara, Gianfrancesco, Milena A., Carrara, Greta, Scirè, Carlo Alberto, Zanetti, Anna, and Machado, Pedro M.

Published
2024
Full Text
View/download PDF

10. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Author

Dahou, Brahim, Gómez, Gimena, Roberts, Karen, Baez, Roberto M, Castro Coello, Vanessa V, Haye Salinas, María J, Maldonado, Federico N, Reyes, Alvaro A, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan A, Schmid, Maria M, Cosatti, Micaela, Gamba, Maria J, Leandro, Carlevaris, Cusa, María A, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria S, Medina, María A, Savio, Veronica, Rojas Tessel, Romina, Alamino, Rodolfo P, Werner, Marina L, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Maria A, Rodriguez Gil, Gustavo F, Risueño, Fabian, Quaglia, Maria I, Scafati, Julia, Cuchiaro, Natalia L, Rebak, Jonathan E, Pineda, Susana I, Calvo, María E, Picco, Eugenia, Yanzi, Josefina G, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta S, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José L, Kisluk, Boris, Castaños Menescardi, Maria S, Gallo, Rosana, Martire, María V, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina S, Aeschlimann, Carolina, Subils, Gisela, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra L, Pinheiro, Marcelo, Ibáñez, Sebastián, Chassin Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešić, Marko, Anić, Branimir, Ćulo, Melanie-Ivana, Pavelić, Tea A, Stranski, Kristina K, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela M, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zazueta Montiel, Beatriz E, Castillo Ortiz, Angel A, Zamora Tehozol, Erick, Vega Morales, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez Reyna, Tatiana S, Rull Gabayet, Marina, Alpízar Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte Gil, Manuel, Nowakowski, Jarosław, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria M, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Mičeková, Dagmar, Capova, Lubica, Macejova, Zelmira, Šteňová, Emőke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Senčarová, Marieta, Žlnayová, Soňa, Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre Rubio, Natalia, Alegre Sancho, Juan J, Corteguera Coro, Montserrat, Cobeta Garcia, Juan C, Torres Martin, Maria C, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd K, Akar, Servet, Icacan, Ozan C, ÇELİK, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline M, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, Todd, Derrick, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio, Karen, Webb Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Ezzati, Fatemeh, Parks, Deborah, Karp, David, Quiceno, Guillermo, Izadi, Zara, Gianfrancesco, Milena A, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Ja, Clairissa, Taylor, Tiffany, Shidara, Kie, Danila, Maria I, Wysham, Katherine D, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O, Ugarte-Gil, Manuel F, Ljung, Lotta, Scirè, Carlo A, Carrara, Greta, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Thomas, Thierry, Santos, Maria J, Bernardes, Miguel, Hasseli, Rebecca, Regierer, Anne, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Pons-Estel, Guillermo, Nieto, Romina E, Pisoni, Cecilia N, Tissera, Yohana S, Xavier, Ricardo, Lopes Marques, Claudia D, Pileggi, Gecilmara C S, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Gore-Massy, Monique, Wallace, Zachary S, and Yazdany, Jinoos

Published
2022
Full Text
View/download PDF

11. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra Lucia, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Castro Coello, Vanessa, Haye Salinas, María J., Maldonado, Federico Nicolas, Reyes Torres, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Rojas Tessel, Ivana Romina, Perez Alamino, Rodolfo, Werner, Marina Laura, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Ma. Alicia, Rodriguez Gil, Gustavo Fabián, Risueño, Fabian, Quaglia, Maria Isabel, Scafati, Julia, Cuchiaro, Natalia Lili, Rebak, Jonathan Eliseo, Pineda, Susana Isabel, Calvo, María Elena, Picco, Eugenia, Gallino Yanzi, Josefina, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José Luis, Kisluk, Boris, Castaños Menescardi, Maria Sol, Gallo, Rosana, Martire, María Victoria, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina Solange, Aeschlimann, Carolina, Subils, Gisela, Ibáñez, Sebastián, Chassin-Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešic, Marko, Anic, Branimir, Culo, Melanie-Ivana, Pavelic, Tea Ahel, Kovacevic Stranski, Kristina, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela Maria, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir-Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zaueta, Beatriz, Castillo Ortiz, Angel Alejandro, Zamora Tehozol, Erick, Vega, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez-Reyna, Tatiana Sofia, Rull Gabayet, Marina, Alpízar-Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts-van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al-Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte-Gil, Manuel, Nowakowski, Jaroslaw, Al-Emadi, Samar, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria Magdelena, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Miceková, Dagmar, Capova, Lubica, Macejova, Zelmira, Štenová, Emoke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Sencarová, Marieta, Žlnayová, Sona, Anna Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre-Rubio, Natalia, Alegre Sancho, Juan José, Corteguera Coro, Montserrat, Cobeta Garcia, Juan Carlos, Torres Martin, Maria Carmen, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd Kubra, Akar, Servet, Icacan, Ozan Cemal, Çelik, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, D'Silva, Kristin, Hsu, Tiffany, Patel, Naomi, Sparks, Jeffrey, Todd, Derrick, Wallace, Zachary, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Wise, Leanna, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio Toribio, Karen, Webb-Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Fatemeh, Ezzati, Parks, Deborah, Karp, David, Quiceno, Guillermo, Sattui, Sebastian E, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, and Robinson, Philip C

Published
2021
Full Text
View/download PDF

13. Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance

Author

Ugarte‐Gil, Manuel F., Alarcón, Graciela S., Seet, Andrea M., Izadi, Zara, Montgomery, Anna D., Duarte‐García, Alí, Gilbert, Emily L., Valenzuela‐Almada, Maria O., Wise, Leanna, Sparks, Jeffrey A., Hsu, Tiffany Y.‐T., DʼSilva, Kristin M., Patel, Naomi J., Sirotich, Emily, Liew, Jean W., Hausmann, Jonathan S., Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Wallace, Zachary, Jacobsohn, Lindsay, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Machado, Pedro M., Robinson, Philip C., Gianfrancesco, Milena, and Yazdany, Jinoos

Published
2023
Full Text
View/download PDF

15. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People with Rheumatic Diseases

Author

Yazdany, Jinoos, primary, Ware, Anna, additional, Wallace, Zachary S, additional, Bhana, Suleman, additional, Grainger, Rebecca, additional, Hachulla, Eric, additional, Richez, Christophe, additional, Cacoub, Patrice, additional, Hausmann, Jonathan S, additional, Liew, Jean W, additional, Sirotich, Emily, additional, Jacobsohn, Lindsay, additional, Strangfeld, Anja, additional, Mateus, Elsa F, additional, Hyrich, Kimme L, additional, Gossec, Laure, additional, Carmona, Loreto, additional, Lawson‐Tovey, Saskia, additional, Kearsley‐Fleet, Lianne, additional, Schaefer, Martin, additional, Ribeiro, Sandra Lucia Euzebio, additional, Al‐Emadi, Samar, additional, Hasseli, Rebecca, additional, Müller‐Ladner, Ulf, additional, Specker, Christof, additional, Schulze‐Koops, Hendrik, additional, Bernardes, Miguel, additional, Machado Fraga, Vanessa, additional, Rodrigues, Ana Maria, additional, Sparks, Jeffrey A., additional, Ljung, Lotta, additional, Di Giuseppe, Daniela, additional, Tidblad, Liselotte, additional, Wise, Leanna, additional, Duarte‐García, Alí, additional, Ugarte‐Gil, Manuel F., additional, Colunga‐Pedraza, Iris Jazmín, additional, Martínez‐Martínez, Marco Ulises, additional, Alpizar‐Rodriguez, Deshire, additional, Xavier, Ricardo Machado, additional, Isnardi, Carolina A, additional, Pera, Mariana, additional, Pons‐Estel, Guillermo, additional, Izadi, Zara, additional, Gianfrancesco, Milena A, additional, Carrara, Greta, additional, Scirè, Carlo Alberto, additional, Zanetti, Anna, additional, and Machado, Pedro M, additional

Published
2023
Full Text
View/download PDF

18. Association Between Race/Ethnicity and COVID ‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID ‐19 Global Rheumatology Alliance

Author

Ugarte‐Gil, Manuel F., primary, Alarcón, Graciela S., additional, Seet, Andrea M., additional, Izadi, Zara, additional, Montgomery, Anna D., additional, Duarte‐García, Alí, additional, Gilbert, Emily L., additional, Valenzuela‐Almada, Maria O., additional, Wise, Leanna, additional, Sparks, Jeffrey A., additional, Hsu, Tiffany Y.‐T., additional, D'Silva, Kristin M., additional, Patel, Naomi J., additional, Sirotich, Emily, additional, Liew, Jean W., additional, Hausmann, Jonathan S., additional, Sufka, Paul, additional, Grainger, Rebecca, additional, Bhana, Suleman, additional, Wallace, Zachary, additional, Jacobsohn, Lindsay, additional, Strangfeld, Anja, additional, Mateus, Elsa F., additional, Hyrich, Kimme L., additional, Gossec, Laure, additional, Carmona, Loreto, additional, Lawson‐Tovey, Saskia, additional, Kearsley‐Fleet, Lianne, additional, Schaefer, Martin, additional, Machado, Pedro M., additional, Robinson, Philip C., additional, Gianfrancesco, Milena, additional, and Yazdany, Jinoos, additional

Published
2022
Full Text
View/download PDF

19. Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases

Author

Izadi, Zara, Gianfrancesco, Milena A., Aguirre, Alfredo, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Seet, Andrea M., Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Al-Emadi, Samar, Sparks, Jeffrey A., Hsu, Tiffany Y.T., Patel, Naomi J., Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O., Ugarte-Gil, Manuel F., Ribeiro, Sandra Lúcia Euzébio, de Oliveira Marinho, Adriana, de Azevedo Valadares, Lilian David, Giuseppe, Daniela Di, Hasseli, Rebecca, Richter, Jutta G., Pfeil, Alexander, Schmeiser, Tim, Isnardi, Carolina A., Reyes Torres, Alvaro A., Alle, Gelsomina, Saurit, Verónica, Zanetti, Anna, Carrara, Greta, Labreuche, Julien, Barnetche, Thomas, Herasse, Muriel, Plassart, Samira, Santos, Maria José, Rodrigues, Ana Maria, Robinson, Philip C., Machado, Pedro M., Sirotich, Emily, Liew, Jean W., Hausmann, Jonathan S., NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Centro de Estudos de Doenças Crónicas (CEDOC)

Subjects
Rheumatology
Abstract

Funding Information: We acknowledge financial support from the ACR and EULAR. The ACR and EULAR were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Publisher Copyright: © 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. Objective: Some patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID-19 ARDS in this population and to create a simple risk score calculator for use in clinical settings. Methods: Data were derived from the COVID-19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID-19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier. Results: The study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67-0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%-83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator. Conclusion: We were able to predict ARDS with good sensitivity using information readily available at COVID-19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID-19 disease progression. publishersversion published

Published
2022

20. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status

Author

Maguire, Sinead, primary, Al-Emadi, Samar, additional, Alba, Paula, additional, Aguiar, Mathia Cecilia, additional, Al Lawati, Talal, additional, Alle, Gelsomina, additional, Bermas, Bonnie, additional, Bhana, Suleman, additional, Branimir, Anic, additional, Bulina, Inita, additional, Clowse, Megan, additional, Cogo, Karina, additional, Colunga, Iris, additional, Cook, Claire, additional, Cortez, Karen J, additional, Dao, Kathryn, additional, Gianfrancesco, Milena, additional, Gore-Massey, Monique, additional, Gossec, Laure, additional, Grainger, Rebecca, additional, Hausman, Jonathon, additional, Hsu, Tiffany Y T, additional, Hyrich, Kimme, additional, Isnardi, Carolina, additional, Kawano, Yumeko, additional, Kilding, Rachael, additional, Kusevich, Daria A, additional, Lawson-Tovey, Saskia, additional, Liew, Jean, additional, McCarthy, Eoghan, additional, Montgumery, Anna, additional, Moyano, Sebastian, additional, Nasir, Noreen, additional, Padjen, Ivan, additional, Papagoras, Charalampos, additional, Patel, Naomi J, additional, Pera, Mariana, additional, Pisoni, Cecilia, additional, Pons-Estel, Guillermo, additional, Quiambao, Antonio L, additional, Quintana, Rosana, additional, Ruderman, Eric, additional, Sattui, Sebastian, additional, Savio, Veronica, additional, Sciascia, Savino, additional, Sencarova, Marieta, additional, Morales, Rosa Serrano, additional, Siddique, Faizah, additional, Sirotich, Emily, additional, Sparks, Jeffrey, additional, Strangfeld, Anja, additional, Sufka, Paul, additional, Tanner, Helen, additional, Tissera, Yohana, additional, Wallace, Zachary, additional, Werner, Marina L, additional, Wise, Leanna, additional, Worthing, Angus B, additional, Zell, JoAnn, additional, Zepa, Julija, additional, Machado, Pedro M, additional, Yazdany, Jinoos, additional, Robinson, Philip, additional, and Conway, Richard, additional

Published
2022
Full Text
View/download PDF

22. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry

Author

Liew, Jean, primary, Gianfrancesco, Milena, additional, Harrison, Carly, additional, Izadi, Zara, additional, Rush, Stephanie, additional, Lawson-Tovey, Saskia, additional, Jacobsohn, Lindsay, additional, Ja, Clairissa, additional, Hyrich, Kimme L, additional, Gossec, Laure, additional, Strangfeld, Anja, additional, Carmona, Loreto, additional, Schäfer, Martin, additional, Frãzao-Mateus, Elsa, additional, Bulina, Inita, additional, Stafford, Frances, additional, Tufan, Abdurrahman, additional, Graver, Christine, additional, Yardımcı, Gözde Kübra, additional, Zepa, Julija, additional, Al Emadi, Samar, additional, Cook, Claire, additional, Abutiban, Fatemah, additional, Dey, Dfiza, additional, Katigbak, Genevieve, additional, Kaufman, Lauren, additional, Kowalski, Emily, additional, Martínez-Martínez, Marco Ulises, additional, Patel, Naomi J, additional, Reyes-Cordero, Greta, additional, Salido, Evelyn, additional, Smith, Ellison, additional, Snow, David, additional, Sparks, Jeffrey, additional, Wise, Leanna, additional, Bhana, Suleman, additional, Gore-Massy, Monique, additional, Grainger, Rebecca, additional, Hausmann, Jonathan, additional, Sirotich, Emily, additional, Sufka, Paul, additional, Wallace, Zachary, additional, Machado, Pedro M, additional, Robinson, Philip C, additional, and Yazdany, Jinoos, additional

Published
2022
Full Text
View/download PDF

23. Country-Level Factors Associated With COVID-19-Related Death in People With Rheumatic Disease: Results From the COVID-19 Global Rheumatology Alliance Registry

Author

Izadi, Zara, primary, Gianfrancesco, Milena A., additional, Schmajuk, Gabriela, additional, Jacobsohn, Lindsay, additional, Katz, Patricia, additional, Rush, Stephanie, additional, Ja, Clairissa, additional, Taylor, Tiffany, additional, Shidara, Kie, additional, Danila, Maria I., additional, Wysham, Katherine D., additional, Strangfeld, Anja, additional, Frãzao Mateus, Elsa, additional, Hyrich, Kimme L., additional, Gossec, Laure, additional, Carmona, Loreto, additional, Lawson-Tovey, Saskia, additional, Kearsley-Fleet, Lianne, additional, Schaefer, Martin, additional, Al-Emadi, Samar, additional, Sparks, Jeffrey A., additional, Hsu, Tiffany Y-T, additional, Patel, Naomi J., additional, Wise, Leanna, additional, Gilbert, Emily, additional, Duarte-García, Alí, additional, Valenzuela-Almada, Maria O., additional, Ugarte-Gil, Manuel F., additional, Ljung, Lotta, additional, Scirè, Carlo A., additional, Carrara, Greta, additional, Hachulla, Eric, additional, RICHEZ, Christophe, additional, CACOUB, Patrice, additional, Thomas, Thierry, additional, Santos, Maria J., additional, Bernardes, Miguel, additional, Hasseli, Rebecca, additional, Regierer, Anne, additional, Schulze-Koops, Hendrik, additional, Müller-Ladner, Ulf, additional, Pons-Estel, Guillermo, additional, Tanten, Romina, additional, Nieto, Romina E., additional, Pisoni, Cecilia Nora, additional, Tissera, Yohana S., additional, Xavier, Ricardo, additional, Marques, Claudia D. Lopes, additional, Pileggi, Gecilmara Cristina Salviato, additional, Robinson, Philip C., additional, Machado, Pedro M., additional, Sirotich, Emily, additional, Liew, Jean W., additional, Hausmann, Jonathan S., additional, Sufka, Paul, additional, Grainger, Rebecca, additional, Bhana, Suleman, additional, Gore-Massy, Monique, additional, Wallace, Zachary S., additional, Yazdany, Jinoos, additional, and Registry, Global Rheumatology Alliance, additional

Published
2022
Full Text
View/download PDF

25. COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance.

Author

Bermas, Bonnie L., Gianfrancesco, Milena, Tanner, Helen L., Seet, Andrea M., Aguiar, Mathia C., Al Adhoubi, Nasra K., Al Emadi, Samar, Cunha, Bernardo M., Flood, Rachael, Kusevich, Daria A., McCarthy, Eoghan M., Patel, Naomi J., Ruderman, Eric M., Sattui, Sebastian E., Sciascia, Savino, Siddique, Faizah, Valenzuela-Almada, Maria O., Wise, Leanna M., Worthing, Angus B., and Zell, JoAnn

Published
2022
Full Text
View/download PDF

27. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis.

Author

Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-García A, Tseng LY, Cabrera DM, Chock YPE, Degirmenci HB, Duff E, Egeli BH, Graef ER, Gupta A, Harkins P, Hoyer BF, Jayatilleke A, Jin S, Kasia C, Khilnani A, Kilian A, Kim AHJ, Lin CMA, Low C, Proulx L, Sattui SE, Singh N, Sparks JA, Tam H, Ugarte-Gil MF, Ung N, Wang K, Wise LM, Yang Z, Young KJ, Liew JW, Grainger R, Wallace ZS, and Hsieh E

Subjects
Hospitalization, Humans, Muscular Diseases, Respiration, Artificial, SARS-CoV-2, COVID-19, Rheumatic Diseases epidemiology
Abstract

Objective: The relative risk of SARS-CoV-2 infection and COVID-19 disease severity among people with rheumatic and musculoskeletal diseases (RMDs) compared to those without RMDs is unclear. This study was undertaken to quantify the risk of SARS-CoV-2 infection in those with RMDs and describe clinical outcomes of COVID-19 in these patients., Methods: We conducted a systematic literature review using 14 databases from January 1, 2019 to February 13, 2021. We included observational studies and experimental trials in RMD patients that described comparative rates of SARS-CoV-2 infection, hospitalization, oxygen supplementation/intensive care unit (ICU) admission/mechanical ventilation, or death attributed to COVID-19. Methodologic quality was evaluated using the Joanna Briggs Institute critical appraisal tools or the Newcastle-Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated, as applicable for each outcome, using the Mantel-Haenszel formula with random effects models., Results: Of the 5,799 abstracts screened, 100 studies met the criteria for inclusion in the systematic review, and 54 of 100 had a low risk of bias. Among the studies included in the meta-analyses, we identified an increased prevalence of SARS-CoV-2 infection in patients with an RMD (RR 1.53 [95% CI 1.16-2.01]) compared to the general population. The odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and those without an RMD, whereas the mortality rate was increased in patients with RMDs (OR 1.74 [95% CI 1.08-2.80]). In a smaller number of studies, the adjusted risk of outcomes related to COVID-19 was assessed, and the results varied; some studies demonstrated an increased risk while other studies showed no difference in risk in patients with an RMD compared to those without an RMD., Conclusion: Patients with RMDs have higher rates of SARS-CoV-2 infection and an increased mortality rate., (© 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)

Published
2022
Full Text
View/download PDF

28. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.

Author

Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, and Kappelman MD

Subjects
Adult, Arthritis, Rheumatoid epidemiology, Comorbidity, Drug Therapy, Combination adverse effects, Female, Hospitalization statistics & numerical data, Humans, Inflammatory Bowel Diseases epidemiology, Male, Middle Aged, Pandemics, Psoriasis epidemiology, Registries, Retrospective Studies, SARS-CoV-2, Arthritis, Rheumatoid drug therapy, COVID-19 mortality, Inflammatory Bowel Diseases drug therapy, Psoriasis drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use
Abstract

Importance: Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood., Objective: To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19-associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs., Design, Setting, and Participants: This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included., Exposures: Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy., Main Outcomes and Measures: The main outcome was COVID-19-associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations., Results: A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age was 48.8 (16.5) years. The most common IMID diagnoses were rheumatoid arthritis (2146 patients [35.3%]) and Crohn disease (1537 patients [25.3%]). A total of 1297 patients (21.3%) were hospitalized, and 189 patients (3.1%) died. In the pooled analysis, compared with patients who received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI, 1.17-2.58; P = .006), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; P = .001), methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; P < .001), and Jak inhibitor monotherapy (OR, 1.82; 95% CI, 1.21-2.73; P = .004) but not among those who received a TNF inhibitor in combination with methotrexate therapy (OR, 1.18; 95% CI, 0.85-1.63; P = .33). Similar findings were obtained in analyses that accounted for potential reporting bias and sensitivity analyses that excluded patients with a COVID-19 diagnosis based on symptoms alone., Conclusions and Relevance: In this cohort study, TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with IMIDs.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results